Recent Updates
Recently added Catalysts
NBTX Neutral Sentiment

Voting Rights and Shares Capital of the Company

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the voting rights and share capital of a company, referencing specific articles of the French Commercial Code and regulations from the French Financial Markets Authority. It is dated July 30, 2026, and mentions the market as Euronext Paris and Nasdaq Euronext. No specific developments or changes are detailed.
Price reaction · baseline $40.155 (2026-07-30 close) · hit after-hours · clean, no other NBTX news in the window
day 0 close · peak
-4.4%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
3%
average across 5 past catalysts
Lead asset
NBTXR3
Phase 2 · Adult Soft Tissue Sarcoma

Full Press Release Details

PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, July 30, 2026 Market: Euronext Paris / Nasdaq Euronext
ShareAdd on Google
Tags: NBTX Viatris Investor Conferences Healthcare voting rights share capital Euronext Paris French regulations
Last updated: Jul 30, 2026

Biotech snapshot

Lead asset
NBTXR3Phase 2
Adult Soft Tissue Sarcoma →

Catalyst track record

+63%
best trade around NBTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for NBTX.

See every catalyst's timing & PoA →